Reference(s)
Click here to return to the Reference Table

Descriptor: Poor Prognosis


Acute Myelogenous Leukemia

Adult T Cell Leukemia

Reference Number: 690
Onimaru Y, Tsukasaki K, Murata K, Imaizumi Y, Choi YL, Hasegawa H, Sugahara K, Yamada Y, Hayashi T, Nakashima M, Taguchi T, Mano H, Kamihira S, Tomonaga M. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met. Int J Oncol. 33, 697-703 (2008)
PubMed link      E-mail link

Bladder

Reference Number: 3
Cheng, H. L. et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 20, 1544-50. (2002).
PubMed link      E-mail link

Reference Number: 455
Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer. 92, 1906-14 (2005)
PubMed link      E-mail link

Reference Number: 592
Wang P, Nishitani MA, Tanimoto S, Kishimoto T, Fukumori T, Takahashi M, Kanayama HO. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology. 69, 780-4 (2007)
PubMed link      E-mail link

Reference Number: 808
Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol. 40, 496-504 (2009)
PubMed link      E-mail link

Reference Number: 1834
Kim YW, Yun SJ, Jeong P, Kim SK, Kim SY, Yan C, Seo SP, Lee SK, Kim J, Kim WJ The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease. PLoS One. 10, e0134552 (2015)
PubMed link      E-mail link

Breast

Reference Number: 6
Edakuni, G., Sasatomi, E., Satoh, T., Tokunaga, O. & Miyazaki, K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 51, 172-8. (2001).
PubMed link      E-mail link

Reference Number: 8
Kang, J. Y. et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63, 1101-5 (2003).
PubMed link      E-mail link

Reference Number: 9
Nagy, J. et al. Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg Oncol 5, 15-21. (1996).
PubMed link      E-mail link

Reference Number: 11
Yamashita, J. et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54, 1630-3 (1994).
PubMed link      E-mail link

Reference Number: 14
Camp, R. L., Rimm, E. B. & Rimm, D. L. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86, 2259-65. (1999).
PubMed link      E-mail link

Reference Number: 16
Tsarfaty, I. et al. Alteration of Met protooncogene product expression and prognosis in breast carcinomas. Anal Quant Cytol Histol 21, 397-408. (1999).
PubMed link      E-mail link

Reference Number: 232
Tolgay Ocal, I, Dolled-Filhart, M, D'Aquila, TG, Camp, RL, & Rimm, DL.  Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 97:1841-8 (2003).
PubMed link      E-mail link

Reference Number: 331
Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res11, 2222-8 (2005)
PubMed link      E-mail link

Reference Number: 332
Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer  113, 678-82 (2005)
PubMed link      E-mail link

Reference Number: 360
Sheen-Chen SM, Liu YW, Eng HL, Chou FF. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev. 14 715-7 (2005)
PubMed link      E-mail link

Reference Number: 526
Pozner-Moulis S, Cregger M, Camp RL, Rimm DL. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest. 87, 251-60 (2007)
PubMed link      E-mail link

Reference Number: 548
Chen HH, Su WC, Lin PW, Guo HR, Lee WY. Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res Treat. 103, 167-75 (2007)
PubMed link      E-mail link

Reference Number: 556
Garcia S, Dalès JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, Charpin C. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol. 38, 830-41 (2007)
PubMed link      E-mail link

Reference Number: 574
Götte M, Kersting C, Radke I, Kiesel L, Wülfing P. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res. 9, R8 (2007)
PubMed link      E-mail link

Reference Number: 576
Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, Charpin C. Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol. 31, 49-58 (2007)
PubMed link      E-mail link

Reference Number: 676
Syed DN, Afaq F, Sarfaraz S, Khan N, Kedlaya R, Setaluri V, Mukhtar H. Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation. Toxicol Appl Pharmacol. 231, 52-60 (2008)
PubMed link      E-mail link

Reference Number: 685
Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A. 106, 12909-14 (2009)
PubMed link      E-mail link

Reference Number: 716
Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A. 106, 12903-8 (2009)
PubMed link      E-mail link

Reference Number: 1177
Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, Sugimoto H, Rocha RM, Damascena A, Brentani RR, Kalluri R. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 21, 66-81 (2012)
PubMed link      E-mail link

Reference Number: 1449
Inanc M1, Ozkan M, Karaca H, Berk V, Bozkurt O, Duran AO, Ozaslan E, Akgun H, Tekelioglu F, Elmali F. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol. 31, 801 (2014)
PubMed link      E-mail link

Reference Number: 1874
Yan S, Jiao X, Zou H, Li K. Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases. Diagn Pathol. 10, 62 (2015)
PubMed link      E-mail link

Cervical

Reference Number: 29
Baykal, C., Ayhan, A., Al, A. & Yuce, K. Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol Oncol 88, 123-9. (2003).
PubMed link      E-mail link

Reference Number: 398
Tsai HW, Chow NH, Lin CP, Chan SH, Chou CY, Ho CL. The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma. Hum Pathol. 37, 198-204. Epub 2005 Dec 20 (2006)
PubMed link      E-mail link

Reference Number: 466
Leo C, Horn LC, Einenkel J, Hentschel B, Hockel M. Tumor hypoxia and expression of c-met in cervical cancer. Gynecol Oncol. 104, 181-5 (2007)
PubMed link      E-mail link

Reference Number: 1365
Kim BW1, Cho H, Chung JY, Conway C, Ylaya K, Kim JH, Hewitt SM. Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry. J Transl Med. 11, 185 (2013)
PubMed link      E-mail link

Cholangiocarcinoma

Reference Number: 1121
Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 105, 131-8 (2011)
PubMed link      E-mail link

Reference Number: 1782
Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows J. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One. 9, e100586 (2014)
PubMed link      E-mail link

Chronic Myeloid Leukemia

Reference Number: 273
Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY, Suh JS, Chae SC, Lee KS, Lee KB. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma. 46, 885-91 (2005)
PubMed link      E-mail link

Colorectal

Reference Number: 480
Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248, 219-28 (2007)
PubMed link      E-mail link

Reference Number: 485
Inoue Y, Miki C, Watanabe H, Ojima E, Kusunoki M. Genomic instability and tissue expression of angiogenic growth factors in sporadic colorectal cancer. Surgery. 139, 305-11 (2006)
PubMed link      E-mail link

Reference Number: 734
Miki C, Inoue Y, Hiro J, Ojima E, Araki T, Uchida K, Kusunoki M. Combined measurement of hepatocyte growth factor and carcinoembryonic antigen as a prognostic marker for patients with dukes a and B colorectal cancer: results of a five-year study. Dis Colon Rectum. 49, 1710-8 (2006)
PubMed link      E-mail link

Reference Number: 837
Osada S, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, Tanaka Y, Tokuyama Y, Okumura N, Nonaka K, Hosono Y, Takahashi T, Yamaguchi K, Yoshida K. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology. 57, 76-80 (2010)
PubMed link      E-mail link

Reference Number: 1056
Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer. 10, 325-32 (2011)
PubMed link      E-mail link

Reference Number: 1157
Liu Y, Li Q, Zhu L. Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. Tumori. 98, 105-12 (2012)
PubMed link      E-mail link

Reference Number: 1328
Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis. 28, 9-18 (2013)
PubMed link      E-mail link

Reference Number: 1434
Samamé Pérez-Vargas JC1, Biondani P, Maggi C, Gariboldi M, Gloghini A, Inno A, Volpi CC, Gualeni AV, di Bartolomeo M, de Braud F, Castano A, Bossi I, Pietrantonio F. Role of cMET in the development and progression of colorectal cancer. Int J Mol Sci. 14, 18056-77 (2013)
PubMed link      E-mail link

Reference Number: 1436
Bendell JC1, Ervin TJ, Gallinson D, Singh J, Wallace JA, Saleh MN, Vallone M, Phan SC, Hack SP. Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer. 12, 218-22 (2013)
PubMed link      E-mail link

Reference Number: 1447
Takahashi N1, Yamada Y1, Furuta K2, Honma Y1, Iwasa S1, Takashima A1, Kato K1, Hamaguchi T1, Shimada Y1. Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. Br J Cancer. 110, 2716-27 (2014)
PubMed link      E-mail link

Reference Number: 1656
Lee J, Jain A, Kim P, Lee T, Kuller A, Princen F, In-GuDo, Kim SH, Park JO, Park YS, Singh S, Kim HC. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. PLoS One. 9, e103551 (2014)
PubMed link      E-mail link

Reference Number: 1832
Seo AN, Park KU, Choe G, Kim WH, Kim DW, Kang SB, Lee HS. Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients. Tumour Biol. 36, 9813-21 (2015)
PubMed link      E-mail link

Reference Number: 1859
Liu Y, Yu XF, Zou J, Luo ZH. Prognostic value of c-Met in colorectal cancer: a meta-analysis. World J Gastroenterol. 21, 3706-10 (2015)
PubMed link      E-mail link

Endometrial

Esophogeal

Reference Number: 405
Tuynman JB, Buskens CJ, Kemper K, ten Kate FJ, Offerhaus GJ, Richel DJ, van Lanschot JJ. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg. 242, 840-9 (2005)
PubMed link      E-mail link

Reference Number: 487
Anderson MR, Harrison R, Atherfold PA, Campbell MJ, Darnton SJ, Obszynska J, Jankowski JA. Met receptor signaling: a key effector in esophageal adenocarcinoma. Clin Cancer Res. 12, 5936-43 (2006)
PubMed link      E-mail link

Reference Number: 1787
Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows J. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One. 9, e100586 (2014)
PubMed link      E-mail link

Reference Number: 1869
Ozawa Y, Nakamura Y, Fujishima F, Felizola SJ, Takeda K, Okamoto H, Ito K, Ishida H, Konno T, Kamei T, Miyata G, Ohuchi N, Sasano H. c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target. BMC Cancer. 15, 451 (2015)
PubMed link      E-mail link

Gastric

Reference Number: 41
Wu, C. W. et al. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 5, 817-22. (1998).
PubMed link      E-mail link

Reference Number: 44
Taniguchi, K. et al. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82, 2112-22 (1998).
PubMed link      E-mail link

Reference Number: 396
Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, Hölscher AH, Mönig SP. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep. 19, 1477-83 (2008)
PubMed link      E-mail link

Reference Number: 452
Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, Aoki T, Ohnuma S, Aoki T. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer. 8, 124-31 (2005)
PubMed link      E-mail link

Reference Number: 667
Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of Met-expressing human cancer xenografts with (89)Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008 May 20. [Epub ahead of print]
PubMed link      E-mail link

Reference Number: 1039
Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 29, 4789-95 (2011)
PubMed link      E-mail link

Reference Number: 1218
Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He WL, Xu JB, Zan WH. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 106, 304-10 (2012)
PubMed link      E-mail link

Reference Number: 1226
Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, Bang YJ, Kim WH. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 107, 325-33 (2012)
PubMed link      E-mail link

Reference Number: 1519
An X, Wang F, Shao Q, Wang FH, Wang ZQ, Wang ZQ, Chen C, Li C, Luo HY, Zhang DS, Xu RH, Li YH. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy. Cancer. 120, 675-82 (2014)
PubMed link      E-mail link

Reference Number: 1529
Peng Z, Zhu Y, Wang Q, Gao J, Li Y, Li Y, Ge S, Shen L. Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis. PLoS One. 9, e84502 (2014)
PubMed link      E-mail link

Reference Number: 1613
Hack SP, Bruey JM, Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget. 5, 2866-80 (2014)
PubMed link      E-mail link

Reference Number: 1840
Janbabai G, Oladi Z, Farazmandfar T, Taghvaei T, Naghshvar F. The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR. J Cancer Res Clin Oncol. 141, 1945-52 (2015)
PubMed link      E-mail link

Glioblastomas/Astrocytomas

Reference Number: 186
Koochekpour, S. et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57, 5391-8 (1997).
PubMed link      E-mail link

Reference Number: 695
Kong DS, Song SY, Kim DH, Joo KM, Yoo JS, Koh JS, Dong SM, Suh YL, Lee JI, Park K, Kim JH, Nam DH. Prognostic significance of c-Met expression in glioblastomas. Cancer. 115, 140-8 (2009)
PubMed link      E-mail link

Reference Number: 1305
Pierscianek D, Kim YH, Motomura K, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Wrede K, Nakazato Y, Tanaka Y, Mariani L, Vital A, Sure U, Ohgaki H. MET gain in diffuse astrocytomas is associated with poorer outcome. Brain Pathol. 23, 13-8 (2013)
PubMed link      E-mail link

Head and Neck

Reference Number: 50
Marshall, D. D. & Kornberg, L. J. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 108, 1413-7 (1998).
PubMed link      E-mail link

Reference Number: 51
Uchida, D. et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 93, 489-96 (2001).
PubMed link      E-mail link

Reference Number: 52
Aebersold, D. M. et al. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 96, 41-54 (2001).
PubMed link      E-mail link

Reference Number: 53
Cortesina, G. et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer 89, 286-92. (2000).
PubMed link      E-mail link

Reference Number: 54
Galeazzi, E. et al. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 254 Suppl 1, S138-43 (1997).
PubMed link      E-mail link

Reference Number: 55
Morello, S. et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J Cell Physiol 189, 285-90 (2001).
PubMed link      E-mail link

Reference Number: 56
Sawatsubashi, M., Sasatomi, E., Mizokami, H., Tokunaga, O. & Shin, T. Expression of c-Met in laryngeal carcinoma. Virchows Arch 432, 331-5 (1998).
PubMed link      E-mail link

Reference Number: 489
Lo Muzio L, Farina A, Coccia E, Capogreco M, Colella G, Leonardi R, Campisi G, Carinci F. Effect of c-Met expression on survival in head and neck squamous cell carcinoma. Tumour Biol. 27, 115-21 (2006)
PubMed link      E-mail link

Reference Number: 537
Endo K, Shirai A, Furukawa M, Yoshizaki T. Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma. Hum Pathol. 37, 1111-6 (2006)
PubMed link      E-mail link

Kaposi's Sarcoma

Reference Number: 494
Puig L, Fernández-Figueras MT, Penín RM, Esquius M, Alomar A, Ariza A. Differential expression of c-Met in Kaposi's sarcoma according to progression stage and HIV infection status. J Cutan Pathol. 26, 227-31 (1999)
PubMed link      E-mail link

Kidney

Reference Number: 493
Choi JS, Kim MK, Seo JW, Choi YL, Kim DH, Chun YK, Ko YH. MET expression in sporadic renal cell carcinomas. J Korean Med Sci. 21, 672-7 (2006)
PubMed link      E-mail link

Reference Number: 539
Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, Osada Y, Kataoka H. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci. 98, 491-8 (2007)
PubMed link      E-mail link

Reference Number: 670
Tanimoto S, Fukumori T, El-Moula G, Shiirevnyamba A, Kinouchi S, Koizumi T, Nakanishi R, Yamamoto Y, Taue R, Yamaguchi K, Nakatsuji H, Kishimoto T, Izaki H, Oka N, Takahashi M, Kanayama HO. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest. 55, 106-11 (2008)
PubMed link      E-mail link

Reference Number: 1336
Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 24, 343-9 (2013)
PubMed link      E-mail link

Leiomyosarcoma

Reference Number: 312
Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100, 12718-23 (2003)
PubMed link      E-mail link

Reference Number: 353
Jiao Y, Zhao P, Zhu J, Grabinski T, Feng Z, Guan X, Skinner RS, Gross MD, Hay RV, Tachibana H, Cao B. Construction of human naive Fab library and characterization of anti-met Fab fragment generated from the library. Mol Biotechnol. 31, 41-54 (2005)
PubMed link      E-mail link

Liver

Reference Number: 76
Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H. & Okamoto, E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 25, 619-23 (1997).
PubMed link      E-mail link

Reference Number: 253
Daveau M, Scotte M, Francois A, Coulouarn C, Ros G, Tallet Y, Hiron M, Hellot MF, Salier JP. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 36:13-41 (2003).
PubMed link      E-mail link

Reference Number: 476
Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 116, 1582-95 (2006)
PubMed link      E-mail link

Reference Number: 504
Gotohda N, Iwagaki H, Ozaki M, Konishi M, Nakagohri T, Takahashi S, Yagi T, Kinoshita T, Tanaka N. The role of a protease inhibitor against hepatectomy. Hepatogastroenterology. 53, 115-9 (2006)
PubMed link      E-mail link

Reference Number: 723
Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, Bai DS, Li JC, Liu KD, Fan J. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology. 49, 491-503 (2009)
PubMed link      E-mail link

Reference Number: 1273
Bozkaya G, Korhan P, Cokakli M, Erdal E, Sagol O, Karademir S, Korch C, Atabey N. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer. 11, 64 (2012)
PubMed link      E-mail link

Reference Number: 1335
Gao J, Feng X, Inagaki Y, Song P, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Des-?-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence. Biosci Trends. 6, 153-9 (2012)
PubMed link      E-mail link

Reference Number: 1899
Zhu C, Utsunomiya T, Ikemoto T, Yamada S, Morine Y, Imura S, Arakawa Y, Takasu C, Ishikawa D, Imoto I, Shimada M. Hypomethylation of long interspersed nuclear element-1 (LINE-1) is associated with poor prognosis via activation of c-MET in hepatocellular carcinoma. Ann Surg Oncol. 21 Suppl 4, S729-35 (2014)
PubMed link      E-mail link

Lung

Reference Number: 92
Ichimura, E., Maeshima, A., Nakajima, T. & Nakamura, T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 87, 1063-9 (1996).
PubMed link      E-mail link

Reference Number: 570
Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J, Fukayama M. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 98, 1006-13 (2007)
PubMed link      E-mail link

Reference Number: 678
Siddiqui SS, Loganathan S, Krishnaswamy S, Faoro L, Jagadeeswaran R, Salgia R. C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biol Ther. 7, 856-63 (2008)
PubMed link      E-mail link

Reference Number: 691
Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 99, 2280-5 (2008)
PubMed link      E-mail link

Reference Number: 898
Go H, Jeon YK, Park HJ, Sung SW, Seo JW, Chung DH. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 3, 305-13 (2010)
PubMed link      E-mail link

Reference Number: 1052
Arriola E, Cañadas I, Arumí-Uría M, Dómine M, Lopez-Vilariño JA, Arpí O, Salido M, Menéndez S, Grande E, Hirsch FR, Serrano S, Bellosillo B, Rojo F, Rovira A, Albanell J. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer. 105, 814-23 (2011)
PubMed link      E-mail link

Reference Number: 1150
Tanaka A, Sueoka-Aragane N, Nakamura T, Takeda Y, Mitsuoka M, Yamasaki F, Hayashi S, Sueoka E, Kimura S. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer. 75, 89-94 (2012)
PubMed link      E-mail link

Reference Number: 1151
Hosoda H, Izumi H, Tukada Y, Takagiwa J, Chiaki T, Yano M, Arai H. Plasma hepatocyte growth factor elevation may be associated with early metastatic disease in primary lung cancer patients. Ann Thorac Cardiovasc Surg. 18, 1-7 (2012)
PubMed link      E-mail link

Reference Number: 1168
Tachibana K, Minami Y, Shiba-Ishii A, Kano J, Nakazato Y, Sato Y, Goya T, Noguchi M. Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis. Lung Cancer. 75, 181-8 (2012)
PubMed link      E-mail link

Reference Number: 1169
Park S, Choi YL, Sung CO, An J, Seo J, Ahn MJ, Ahn JS, Park K, Shin YK, Erkin OC, Song K, Kim J, Shim YM, Han J. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol. 27, 197-207 (2012)
PubMed link      E-mail link

Reference Number: 1217
Ujiie H, Tomida M, Akiyama H, Nakajima Y, Okada D, Yoshino N, Takiguchi Y, Tanzawa H. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. Anticancer Res. 32, 3251-8 (2012)
PubMed link      E-mail link

Reference Number: 1308
Fu L, Guo W, Liu B, Sun L, Bi Z, Zhu L, Wang X, Liu B, Xie Q, Li K. Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer. Biomarkers. 18, 126-35 (2013)
PubMed link      E-mail link

Reference Number: 1331
Masago K, Togashi Y, Fujita S, Sakamori Y, Okuda C, Kim YH, Mio T, Mishima M. Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib. Med Oncol. 29, 1614-21 (2012)
PubMed link      E-mail link

Reference Number: 1554
Cañadas I, Rojo F, Taus Á, Arpí O, Arumí-Uría M, Pijuan L, Menéndez S, Zazo S, Dómine M, Salido M, Mojal S, García de Herreros A, Rovira A, Albanell J, Arriola E. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res. 20, 938-50 (2014)
PubMed link      E-mail link

Reference Number: 1689
Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN. MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis. PLoS One. 9, e107677 (2014)
PubMed link      E-mail link

Reference Number: 1799
Hong JH, Roh KS, Suh SS, Lee S, Sung SW, Park JK, Byun JH, Kang JH. The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients. Tumour Biol. 36, 9327-37 (2015)
PubMed link      E-mail link

Reference Number: 1818
Wang X, Song N, Zhang Y, Cai Y, Liu Y, Qu X, Li Z, Li D, Hou K, Kang J, Hu X. Coexpression of c-Met and Notch-1 correlates with poor prognosis in resected non-small-cell lung cancer. Tumour Biol. 36, 7053-9 (2015)
PubMed link      E-mail link

Lymphomas

Reference Number: 630
Etto L, Lacerda E, Baiocchi O, Silva V, Dalboni M, Alves A, Silva M, Vettore A, Colleoni G. Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. Leuk Lymphoma. 49, 257-64 (2008)
PubMed link      E-mail link

Reference Number: 1338
Huang WT, Chuang SS. High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma. Diagn Pathol. 8, 16 (2013)
PubMed link      E-mail link

Melanoma

Mesothelioma

Reference Number: 416
Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 66, 352-61 (2006)
PubMed link      E-mail link

Reference Number: 1147
Levallet G, Vaisse-Lesteven M, Le Stang N, Ilg AG, Brochard P, Astoul P, Pairon JC, Bergot E, Zalcman G, Galateau-Sallé F. Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group. J Thorac Oncol. 7, 599-606 (2012)
PubMed link      E-mail link

MFH/Fibrosarcoma

Multiple Myeloma

Reference Number: 163
Seidel, C., Borset, M., Hjorth-Hansen, H., Sundan, A. & Waage, A. Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. Med Oncol 15, 145-53 (1998).
PubMed link      E-mail link

Reference Number: 164
Seidel, C. et al. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol 119, 672-6 (2002).
PubMed link      E-mail link

Reference Number: 165
Turesson, I. et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 106, 1005-12 (1999).
PubMed link      E-mail link

Reference Number: 515
Kara IO, Sahin B, Gunesacar R, Unsal C. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma. Adv Ther. 23, 635-45 (2006)
PubMed link      E-mail link

Reference Number: 809
Ludek P, Hana S, Zdenek A, Martina A, Dana K, Tomas B, Lucie K, Marta K, Jaroslav M, Miroslav P, Jiri V, Roman H. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Eur J Haematol. 84, 332-6 (2010)
PubMed link      E-mail link

Reference Number: 810
Pour L, Svachova H, Adam Z, Mikulkova Z, Buresova L, Kovarova L, Buchler T, Penka M, Vorlicek J, Hajek R. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma. 57, 29-34 (2010)
PubMed link      E-mail link

Nasopharyngeal

Reference Number: 104
Qian, C. N. et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62, 589-96 (2002).
PubMed link      E-mail link

Reference Number: 795
Xie LQ, Bian LJ, Li Z, Li Y, Liang YJ. Co-elevated expression of hepatocyte growth factor and Interleukin-8 contributes to poor prognosis of patients with primary nasopharyngeal carcinoma. Oncol Rep. 23, 141-50 (2010)
PubMed link      E-mail link

Reference Number: 796
Li-juan B, Bing L, Zhi L, Yang L, Ying-jie L. Hepatocyte growth factor suppresses tumor cell apoptosis in nasopharyngeal carcinoma by upregulating Bcl-2 protein expression. Pathol Res Pract. 205, 828-37 (2009)
PubMed link      E-mail link

Reference Number: 1841
Li Y, Li W, He Q, Xu Y, Ren X, Tang X, Wen X, Yang X, Sun Y, Zeng J, Yun J, Liu N, Ma J. Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma. Oncotarget. 6, 13309-19 (2015)
PubMed link      E-mail link

Osteosarcoma

Ovarian

Reference Number: 436
Ayhan A, Ertunc D, Tok EC, Ayhan A. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer. 15, 618-23 (2005)
PubMed link      E-mail link

Reference Number: 827
Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 67, 1670-9 (2007)
PubMed link      E-mail link

Reference Number: 833
Xie LQ, Bian LJ, Li Z, Li Y, Liang YJ. Co-elevated expression of hepatocyte growth factor and Interleukin-8 contributes to poor prognosis of patients with primary nasopharyngeal carcinoma. Oncol Rep. 23, 141-50 (2010)
PubMed link      E-mail link

Reference Number: 843
Drenberg CD, Saunders BO, Wilbanks GD, Chen R, Nicosia RF, Kruk PA, Nicosia SV. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. Gynecol Oncol. 117, 117-24 (2010)
PubMed link      E-mail link

Reference Number: 992
Aune G, Lian AM, Tingulstad S, Torp SH, Forsmo S, Reseland JE, Stunes AK, Syversen U. Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol. 121, 402-6 (2011)
PubMed link      E-mail link

Pancreas/Gall Bladder

Reference Number: 919
Hill KS, Lorinczi M, Elferink LA. Altered down regulation of the receptor tyrosine kinase met in pancreatic adenocarcinoma cells. J Exp Ther Oncol. 8, 297-312 (2010)
PubMed link      E-mail link

Reference Number: 1223
Yang L, Guo T, Jiang S, Yang Z. Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder. Hepatogastroenterology. 59, 1769-75 (2012)
PubMed link      E-mail link

Prostate

Reference Number: 386
Hashem M, Essam T. Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer. J Egypt Natl Canc Inst. 17, 114-20 (2005)
PubMed link      E-mail link

Reference Number: 475
Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer. 4, 269-74 (2006)
PubMed link      E-mail link

Reference Number: 538
Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 67, 967-75 2007
PubMed link      E-mail link

Reference Number: 1639
Nishida S, Hirohashi Y, Torigoe T, Nojima M, Inoue R, Kitamura H, Tanaka T, Asanuma H, Sato N, Masumori N. Expression of hepatocyte growth factor in prostate cancer may indicate a biochemical recurrence after radical prostatectomy. Anticancer Res. 35, 413-8 (2015)
PubMed link      E-mail link

Rhabdomyosarcoma

Reference Number: 572
Chen Y, Takita J, Mizuguchi M, Tanaka K, Ida K, Koh K, Igarashi T, Hanada R, Tanaka Y, Park MJ, Hayashi Y. Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression. Genes Chromosomes Cancer. 46, 348-58 (2007)
PubMed link      E-mail link

Synovial Sarcoma

Thyroid

Reference Number: 130
Di Renzo, M. F. et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7, 2549-53 (1992).
PubMed link      E-mail link

Reference Number: 565
Siraj AK, Bavi P, Abubaker J, Jehan Z, Sultana M, Al-Dayel F, Al-Nuaim A, Alzahrani A, Ahmed M, Al-Sanea O, Uddin S, Al-Kuraya KS. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol. 213, 190-9 (2007)
PubMed link      E-mail link

Wilms' Tumor